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Accepted 13 March 2013AbstractObjectives: In a setting with two concurrent treatments, inverse-probability-of-treatment weights can be used to estimate the joint treat-
ment effects or the marginal effect of one treatment while taking the other to be a confounder. We explore these two approaches in a study
of intravenous iron use in hemodialysis patients treated concurrently with epoetin alfa (EPO).
Study Design and Setting: We linked US Renal Data System data with electronic health records (2004e2008) from a large dialysis
provider. Using a retrospective cohort design with 776,203 records from 117,050 regular hemodialysis patients, we examined a composite
outcome: mortality, myocardial infarction, or stroke.
Results: With EPO as a joint treatment, inverse-probability-of-treatment weights were unstable, confidence intervals for treatment ef-
fects were wide, covariate balance was unsatisfactory, and the treatment and outcome models were sensitive to omission of the baseline
EPO covariate. By handling EPO exposure as a confounder instead of a joint treatment, we derived stable weights and balanced treatment
groups on measured covariates.
Conclusions: In settings with concurrent treatments, if only one treatment is of interest, then including the other in the treatment model
as a confounder may result in more stable treatment effect estimates. Otherwise, extreme weights may necessitate additional analysis
steps.  2013 Elsevier Inc.
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Inverse-probability-of-treatmenteweighted (IPTW) esti-
mation is now commonly used to control for confounding
in nonexperimental studies of medical interventions
[1e3]. IPTW estimation requires that the analyst specify
a model of the treatment rather than the outcome. The fitted
treatment model is then used to estimate inverse-
probability-of-treatment weights that are applied to each
subject. If the treatment model is correctly specified, the re-
weighting results in a population of patients in whom treat-
ment assignment is unrelated to the baseline variables thatConflicts of interest: In the past 5 years, A.R.E. has received
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Open access under CC BY-NC-ND license.are included in the treatment model. Under the assumptions
of exchangeability, positivity, consistency, and a correctly
specified treatment model [1,4,5], IPTW estimation results
in estimates that can be interpreted as the average treatment
effect (ATE) in the population being studied. (Informally,
exchangeability refers to the absence of unmeasured con-
founders, positivity requires that each subject have a non-
zero probability of receiving each of the treatments being
compared, and consistency means that the observed out-
come equals the counterfactual outcome of the treatment
actually received.) The IPTW approach is attempting to
mimic a situation in which treatment is randomly allocated
to individuals.
IPTW estimation can be extended to settings with con-
currently administered treatments. Herein, one is attempt-
ing to estimate the average joint effect of the treatments.
Thus, IPTW estimation is attempting to mimic a situation
in which each concurrent treatment is randomized individ-
ually. This requires that one construct a model of the prob-
ability that a patient would receive any particular
combination of the treatments being studied.
S52 A.R. Ellis, M.A. Brookhart / Journal of Clinical Epidemiology 66 (2013) S51eS56What is new?
 Inverse-probability-of-treatmenteweighted (IPTW)
estimation can be applied to two or more concur-
rently administered treatments.
 In this setting, IPTW estimation may be more
likely to result in large weights and estimates that
are very sensitive to model specification.
 If only one treatment is of interest, then including
the other treatment in the treatment model as a con-
founder may result in more stable estimates of the
effect of interest.
 In studies of concurrent treatments, analysts using
IPTW methods should be vigilant for problems
arising from large weights. In some settings, it
may be more feasible to estimate the marginal ef-
fect of a single treatment.
 If a joint treatment effect is of interest, extreme in-
verse probability of treatment weights may need to
be addressed by excluding observations whose co-
variate values are rare in any treatment group, by
limiting the analysis to common treatment regimes,
or through other means.
IPTW estimates can be highly unstable in the presence
of large weights because the estimates may be driven by
outcomes occurring in a small number of patients [6e8].
This can happen if patients are treated contrary to indica-
tion, the population is poorly defined (i.e., includes patient
subgroups that rarely receive treatment), or the treatment
model is misspecified (i.e., predicted probabilities of treat-
ment are incorrect). Large weights may be particularly
likely in settings with concurrent treatments, where there
may be many treatment categories, some treatment combi-
nations may be uncommon, and correct specification of the
treatment model may be more difficult.
In a setting with concurrent treatments, if interest fo-
cuses primarily on the effect of one treatment, IPTW esti-
mation can be used to estimate the marginal effect of the
treatment of interest, taking the concurrently used treat-
ments to be confounders. This simplifies the estimation of
the treatment model. It also imposes fewer assumptions
on the analysis because exchangeablility, positivity, and
consistency need to hold for only one treatment.
We explore these issues in a study of iron treatment out-
comes in hemodialysis patients, a setting in which concur-
rent use of erythropoiesis-stimulating agents (ESAs) must
be addressed and extreme weights are known to be prob-
lematic [9]. Specifically, our study examines the effect of
iron treatment administered at a point in time, as measured
during a 1-month exposure period, on a composite cardio-
vascular outcome.2. Background
2.1. Anemia management in hemodialysis patients
Anemia affects about 10% of patients in the early stages
of chronic kidney disease and more than 70% of patients
with end-stage renal disease (ESRD) [10]. The anemia of
ESRD is primarily caused by impaired production of renal
erythropoietin. It is worsened by dialysis-related blood loss,
which depletes iron reserves [11]. The anemia of ESRD in-
volves treatment with ESAs to stimulate the production of
red blood cells and administration of intravenous iron to ad-
dress iron deficiency [12].
Several biological mechanisms suggest potential risks
associated with the use of iron [13]. For example, frequent
iron administration may lead to oversaturation of transfer-
rin and the release of free, catalytically active iron into
the plasma [14]. Free iron is also known to catalyze the for-
mation of highly reactive oxygen species [15,16]. These
could give rise to lipid radicals, which may damage the
vasculature [17] and lead to atherogenesis [18], possibly
increasing the long-term risk of cardiovascular events
[13,19]. However, little is known about the relation be-
tween iron dose and cardiovascular outcomes.
We recently undertook a study in which we used data
from the US Renal Data System linked with data from di-
alysis providers to assess the relative safety and effective-
ness of different iron formulations and dosing strategies.
We used multivariable models to examine multiple out-
comes, including cardiovascular events and mortality. To
minimize bias owing to confounding factors, we sought
to implement IPTW estimation. Because joint treatment
with ESAs and iron complicated the IPTW analysis, we
conducted sensitivity analyses to identify the best way to
model treatment. To demonstrate the sensitivity of treat-
ment effect estimates to the treatment model, we used as
an example a composite outcome: mortality, myocardial in-
farction, or stroke. In this article, we report the results of
our sensitivity analyses and comment briefly on the han-
dling of concurrent treatments in IPTW analyses.3. Methods
3.1. Data, study design, and sample
Funded by the National Institute of Diabetes and Diges-
tive and Kidney Diseases, the US Renal Data System col-
lects, analyzes, and distributes information about ESRD
treatment in the United States, including data from the
Medical Evidence Report Form, the Medicare Enrollment
Database, the ESRD Death Notification Form, and the stan-
dard analytic files, which contain final action claims data
[20]. We linked US. Renal Data System data with 5 years
of electronic health record data (2004e2008) from a large
US dialysis provider that owns and manages more than
1,500 outpatient dialysis facilities throughout the United
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hospital use were measured in the U.S. Renal Data System;
epoetin alfa (EPO) and iron exposure, laboratory values,
and intravenous antibiotic use were measured in the clinical
database. EPO is a commonly used ESA.
We used a retrospective cohort design. Because transfer-
rin saturation is used to guide iron administration, we
aligned the 1-month exposure period so that it began the
day after a transferrin saturation laboratory test. We used
a 6-month baseline period and followed patients for up to
3 months after exposure. The data structure was designed
to allow us to estimate the effect of iron treatment during
a single 1-month exposure period on short-term outcomes.
We allowed multiple observations per patient, with a mini-
mum of 90 days between index transferrin saturation labo-
ratory tests (i.e., nonoverlapping follow-up periods); each
observation included a 6-month baseline period that imme-
diately preceded the exposure period.
Our sample included incident and prevalent hemodialy-
sis patients who were covered by Medicare Part A and Part
B, received regular center hemodialysis during the baseline
and exposure periods, and received either ferric gluconate
or iron sucrose, but not both, during the exposure period.
We required at least 3 months of dialysis before baseline
to allow for stability in claims processing [21], and ex-
cluded patients with polycystic kidney disease and observa-
tions with missing covariate information. The final sample
included 776,203 records from 117,050 patients.3.2. Measures
We used Medicare claims data from the US Renal Data
System to measure the composite outcome: mortality, myo-
cardial infarction, or stroke. One-month iron exposure,
measured using the detailed clinical data, was classified
as high (O200 mg), low (1e200 mg), or none. One-
month EPO exposure was coded in tertiles. We measured
23 baseline covariates, including age, sex, race, comorbid-
ities, years on dialysis, infection during baseline, and the
use of a catheter as the primary vascular access.3.3. Statistical analysis
We used a generalized logit model to predict EPO treat-
ment category given the baseline covariates. We then used
a second generalized logit model to predict iron treatment
category given EPO treatment and covariates. Although
we could have used ordinal logistic models, such models
require the proportional odds assumption, meaning that
a single coefficient describes the relation between the odds
of being assigned to a given dose level and the odds of be-
ing assigned to the next higher dose level. We believed that
this assumption was unrealistic for our data.
For each observation, the generalized logit models
yielded one predicted probability per treatment category.
That is, each observation received three predictedprobabilities for EPO and three predicted probabilities for
iron. We selected the estimates for the EPO and iron treat-
ments actually received (i.e., one predicted probability for
EPO and another for iron). For each observation, we esti-
mated the probability of receiving the treatment actually re-
ceived as Pr(actual EPO treatment category j covariates)
Pr(actual iron treatment category j actual EPO treatment cat-
egory, covariates). The inverse-probability-of-treatment
weights were calculated as the reciprocal of this value. As-
suming that the treatmentmodel is correct, theseweights cre-
ate a pseudopopulation in which confounders are unrelated
to treatment assignment. Therefore, the weights can be used
to make an unbiased estimate of the treatment effect in the
population. We stabilized the weights by multiplying them
by the marginal probability of receiving the treatment com-
bination actually received. We suspected that the handling
of baseline EPO treatment, like the handling of EPO expo-
sure, might affect the stability of our results. Therefore, our
sensitivity analysis included 12 different treatment models,
representing all possible combinations of three factors:
1. Modeling of EPO exposure (as joint treatment vs.
confounder)
2. Baseline EPO covariate: total number of units of EPO
received during the last month of baseline (categori-
cal variable with five levels, categorical variable with
three levels, or excluded)
3. Patients receiving no EPO during the exposure period
and no EPO during the last month of baseline (in-
cluded vs. excluded)
To clarify the contribution of the EPO exposure variable
to the variability of the inverse-probability-of-treatment
weights, we also ran six models predicting only iron treat-
ment and ignoring EPO treatment. In these models, we var-
ied factors 2 and 3: the baseline EPO covariate and the
handling of the no-EPO group. Weights were calculated
and stabilized in the same way as before based on the prob-
ability of receiving the iron treatment actually received.
We evaluated treatment models with regard to the distri-
bution of the stabilized weights, covariate balance, and sta-
bility of treatment effect estimates. Because we were
interested in contrasting treatment groups with each other,
covariate balance was measured using standardized abso-
lute mean difference on covariates between the high iron
dose group and each of the other two iron dose groups.
Considering all the pairwise standardized absolute mean
differences together, we used the median and maximum
standardized absolute mean difference to characterize the
level of covariate balance. The treatment effect of high iron
dose vs. low iron dose was estimated using Cox propor-
tional hazard models of the time to death, first myocardial
infarction, or first stroke, using the weights to adjust for
confounding. Censoring occurred at transplant, loss to
follow-up, or the end of available data. To account for the
clustering of observations within patients, we used the ro-
bust sandwich estimator to derive standard errors.
Table 1. Weight distribution and covariate balance by treatment model, for models predicting joint iron and EPO treatment
No-EPO group Baseline EPO variable Weight mean (SD) Weight maximum SAMD median SAMD maximum
Included Five categories 1.5 (54.1) 28,050 0.06 0.43
Three categories 1.4 (40.6) 14,955 0.07 0.26
Excluded 1.0 (7.5) 5,859 0.02 0.23
Excluded Five categories 1.4 (41.6) 17,201 0.06 0.25
Three categories 1.3 (40.8) 19,313 0.06 0.34
Excluded 1.0 (9.2) 7,148 0.02 0.25
Abbreviations: EPO, epoetin alfa; SD, standard deviation; SAMD, standardized absolute mean difference.
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mates for the comparison of primary interest (high vs. low
iron dose), we held factors 2 and 3 constant (classifying
baseline EPO into five levels and including patients who re-
ceived no EPO) and compared the EPO-as-joint-treatment
approach to the EPO-as-confounder approach with regard
to main effects and ironeEPO interactions.
This study was approved by the University of North Car-
olina Institutional Review Board.Fig. 1. Effect of high vs. low iron dose by treatment model, for treat-
ment models predicting joint iron and EPO treatment. EPO, epoetin
alfa; MI, myocardial infarction; HR, hazard ratio; CI, confidence
interval.4. Results
4.1. Models predicting joint EPO and iron treatment
When the treatment model predicted both EPO and iron
treatment, the stabilized weights were variable and ranged
as high as 28,050 (Table 1). Balance generally improved
compared with the pre-propensityescoring results (median
standardized absolute mean difference 0.06, maximum
0.55), but imbalance remained on some covariates. Omit-
ting baseline EPO gave the weights a mean of 1.0 and made
them less variable. Excluding nonrecipients of EPO had lit-
tle effect on weight distribution and no clear effect on bal-
ance. Treatment effect estimates for high vs. low iron were
sensitive to the handling of the no-EPO group and the base-
line EPO covariate (Fig. 1). Confidence intervals were
wider when the baseline EPO covariate was included.
4.2. Models predicting only iron treatment, with EPO
treatment as a confounder
Including EPO treatment as a confounder in the treat-
ment model, instead of as a joint treatment, resulted in sta-
bilized weights with a mean of 1.0 and much less variation,
regardless of how the baseline EPO covariate and EPO non-
recipients were handled (Table 2). This set of models also
resulted in improved covariate balance (Table 2) and stable
treatment effect estimates (Fig. 2). The models that ignored
EPO treatment had nearly identical results (not shown).
4.3. Main effects and interactions when holding factors
2 and 3 constant
When we fixed the number of baseline EPO categories at
5 and included patients with no EPO exposure, the model
handling EPO as a joint treatment yielded hazard ratiosof 1.17 (95% confidence interval [CI]: 0.70e1.96) for high
vs. low iron and 0.49 (95% CI: 0.21e1.10) for high vs. no
iron. Hazard ratios for high vs. medium EPO and high vs.
low EPO were 0.90 (95% CI: 0.70e1.17) and 0.39 (95%
CI: 0.13e1.15), respectively.
In the model handling EPO as a confounder, the hazard
ratio for high vs. low iron was 1.05 (95% CI: 1.00e1.09),
and the hazard ratio for high vs. no iron was 1.00 (95%
CI: 0.96e1.06). Confidence intervals were narrower for this
model than for the model handling EPO as a joint treat-
ment. This model did not allow estimation of causal effects
for EPO.
Fig. 3 shows the estimated hazard ratios for high vs. low
dose iron within EPO tertiles by treatment model. When
EPO was handled as a joint treatment, confidence intervals
were much wider, especially for the highest and lowest ter-
tiles of EPO exposure. When EPO was handled as a con-
founder, hazard ratio estimates were more consistent. All
confidence intervals included 1.0.5. Discussion
We considered approaches to IPTW estimation in a set-
ting in which two treatments are used concurrently but one
is of primary interest. In our study of treatment of anemia in
Table 2. Weight distribution and covariate balance by treatment model, for models predicting only iron treatment with EPO treatment as
a confounder
No-EPO group Baseline EPO variable Weight mean (SD) Weight maximum SAMD median SAMD maximum
Included Five categories 1.0 (1.6) 85.8 0.01 0.21
Three categories 1.0 (1.6) 82.5 0.01 0.21
Excluded 1.0 (1.6) 84.6 0.01 0.21
Excluded Five categories 1.0 (1.6) 87.4 0.01 0.21
Three categories 1.0 (1.6) 85.0 0.01 0.21
Excluded 1.0 (1.6) 86.4 0.01 0.21
Abbreviations: EPO, epoetin alfa; SD, standard deviation; SAMD, standardized absolute mean difference.
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intravenous iron and the concurrently used treatment was
EPO. We conducted a series of analyses in which we varied
the treatment model, the handling of the baseline EPO co-
variate, and the inclusion vs. exclusion of patients who re-
ceived EPO during neither the baseline period nor the
exposure period. When the stabilized weights were based
on a model predicting joint treatment, they were poorly be-
haved. They did not have the usual mean of 1.0 and were
highly variable. Although handling EPO as a joint treat-
ment allowed estimation of causal effects for both iron
and EPO as well as interaction effects, the variability in
the weights led to wide confidence intervals for treatment
effect estimates. Also, covariate balance in the reweighted
population was poor, and the treatment and outcome
models were sensitive to the omission of the baseline
EPO covariate.
By including EPO treatment as a confounder instead of
a joint treatment, we were able to derive stable weights and
to balance the treatment groups on measured covariates. Al-
though some residual imbalance remained, it was negligible
for most covariates (median standardized absolute mean
difference 0.01), small (0.21 standard deviation units) even
for the covariate with the most residual imbalance, andFig. 2. Effect of high vs. low iron dose by treatment model, for treat-
ment models predicting only iron treatment with EPO treatment as a
confounder. EPO, epoetin alfa; MI, myocardial infarction; HR, hazard
ratio; CI, confidence interval.acceptable for our purposes. Residual imbalance can be de-
creased by making the treatment model more flexible (e.g.,
adding interaction or spline terms or using nonparametric
estimation). When we ran treatment models that ignored
EPO treatment entirely (not recommended in practice),
the resulting covariate balance and weight distribution were
nearly identical, suggesting that instability owing to the
EPO treatment variable disappeared entirely when EPO
was included as a confounder instead of a joint treatment.
If both of the concurrent treatments had been of substan-
tive interest, extreme weights would have required us to
take additional steps to have an identifiable treatment ef-
fect, such as excluding observations whose covariate values
were rare in any treatment group [22], restricting the set of
treatments to be examined [23], or truncating weights to re-
duce variability [24]. Weight truncation simply reduces ex-
treme weights directly to decrease reliance on a few highly
influential observations that were treated contrary to expec-
tation, decreasing standard errors at the expense of some re-
sidual bias. The other two steps, by removing rare covariate
combinations or rare treatment assignments, eliminateFig. 3. Effect of high vs. low iron dose by treatment model and EPO
exposure tertile. The analysis included patients who did not receive
EPO. In both treatment models, the baseline EPO covariate was clas-
sified into five categories. One treatment model handled EPO expo-
sure as a joint treatment with iron; the other handled EPO exposure
as a confounder. EPO, epoetin alfa; MI, myocardial infarction; HR,
hazard ratio; CI, confidence interval.
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ting, only iron treatment was of interest, and including
EPO treatment as a confounder was an effective way to
achieve stable inverse-probability-of-treatment weights
and still prevent confounding by balancing the treatment
groups on measured covariates.
One subtle drawback to handling concurrent treatments
as confounders is that they become characteristics of the
population for whom the ATE is being estimated. There-
fore, if the use of concurrent treatments changes, the ATE
of the primary treatment may also change. This may limit
the generalizability of the estimate to other patient popula-
tions or time periods where use of the concurrent treatments
may be different. This can be addressed by stratifying the
analysis over levels of the concurrent treatment. Subgroup
effects can then be standardized to a population with a dif-
ferent pattern of concurrent treatment.
Our analysis suggests that IPTWestimation of the joint ef-
fects of concurrent treatments may be challenging in some
situations because it complicates estimation of the treatment
model, imposes more assumptions on the analysis, and may
bemore likely to involve extremeweights. If one treatment is
of primary interest, it may be preferable to take the concur-
rently administered treatment as a confounder. This may re-
sult in estimates that are more stable and valid.Acknowledgments
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